Presbyopia

A look back on what's happened in optometry during the week of February 25-March 2.

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key takeaways from his SECO 2023 presentation, "Drugs of the future."

Milton M. Hom, OD, FAAO, FACAAI (Sc), shares key highlights from his portion of the "Presbyopia management panel," during SECO 2023 in Atlanta.

A look back on what's happened in optometry during the week of February 18-February 23.

A PDUFA goal date of October 22, 2023 was assigned to the investigational eye drop candidate for the treatment of presbyopia.

A look back on what's happened in optometry during the week of Jan. 7-Jan. 12, 2023.

The VEGA-2 pivotal trial is investigating Nyxol alone and Nyxol with adjunctive low-dose pilocarpine therapy for the treatment of presbyopia.

Expert eye care specialists comment on the use of aceclidine as a selective miotic for the treatment of presbyopia.

Marc R. Bloomenstein, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Mile Brujic, OD, FAAO, shares key takeaways from his EyeCon 2022 presentation, "Advances in presbyopia."

Andrew S. Morgenstern discusses the selectivity of miotic agents in isolating the pupil while limiting adverse events for the management of presbyopia.

Francis S. Mah, MD, reviews miotic agents that are available or under investigation for the treatment of presbyopia.

Panel discusses the highs and lows of treating patients with this condition.

Considering safety and efficacy of new drops and the potential impact on your patients.

Sean W. Smolenyak, OD, gives a brief overview of presbyopia, including the cause and available treatments.

Ocuphire seeks to develop and commercialize Nyxol for the reversal of mydriasis, presbyopia and night vision disturbances.

Presbyopia-correcting drops for patients with low, up-close visual function.

Evolution of vision correction procedures, diagnostics paves way for collaborative care.

World Sight Day is upon us and RestoringVision has issued a lofty but doable goal: help solve the global vision crisis.

Experts answer clinicians’ common questions on treating patients.

Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia

Expert advice offers key practice management tips for making presbyopia drops an integrated part of a clinical armamentarium.

Help presbyopia patients by following fitting guides and embracing new adjunct therapy options.

Patients present with a plethora of complaints, with blurred near vision, headache, fatigue, need for increased working distance and brighter light to read among the most common, according to Cecelia Koetting, OD, during AOA 2022.

A pharmaceutical approach (pilocarpine hydrochloride ophthalmic solution 1.25% ) to improving near vision can be used with other technology, benefiting a wide variety of patients.